United Kingdom-based ViiV Healthcare has revealed positive results for its phase three BRIGHTE study of investigational Fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV-1 infection, it was reported yesterday.

The product, in combination with optimised background treatment, maintained virologic suppression from Week 24 to Week 48 in this difficult-to-treat population. Results indicated 54% of patients in the randomised cohort (n = 146/272) achieved virologic suppression (